News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase II
Janssen Research & Development Release: Data Published In The New England Journal of Medicine Show Single-Agent Daratumumab Demonstrated A 36 Percent Overall Response Rate And Tolerable Safety Profile In Heavily Pre-Treated Multiple Myeloma Patients 8/27/2015
Oncolytics Biotech Inc. (ONC.TO) Collaborators To Present Survival Data From REO 016 Study In Non-Small Cell Lung Cancer 8/27/2015
iCo Therapeutics Inc. Announces Second Quarter 2015 Financial Results 8/27/2015
DelMar Pharmaceuticals To Announce Fiscal 2015 Year-End Financial Results On September 4, 2015 8/27/2015
Asterias Biotherapeutics To Present At Upcoming Investor Conferences 8/27/2015
In Response to Twitter Rumors and Phase II Data, Verastem (VSTM) Stock Plunges 8/27/2015
ORYZON To Present At Rodman & Renshaw 17th Annual Global Investment Conference 8/27/2015
Verastem (VSTM) Issues Statement Regarding WCLC Presentations 8/27/2015
Threshold Pharmaceuticals, Inc. (THLD) Initiates Phase 2 Clinical Trial Of Tarloxotinib Bromide (TH-4000) In Patients With Recurrent Or Metastatic Squamous Cell Carcinomas Of The Head And Neck Or Skin 8/27/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Completion Of Enrollment In Randomized Phase II Non-Small Cell Lung Cancer Study 8/26/2015
XTL Biopharmaceuticals Ltd. (XTLB) Announces Publication Of Results Of Phase 2 Study On Hcdr1 (Edratide) In Patients With Active Systemic Lupus Erythematosus (SLE) In Lupus Science & Medicine 8/26/2015
CryoPort, Inc. Supports Opexa Therapeutics (OPXA)' Lead Personalized T-Cell Immunotherapy Programs 8/26/2015
Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant To Develop Its Proteoglycan Mimetic Therapeutics To Reduce Vascular Access Failures In ESRD 8/26/2015
Nordic Nanovector: Results For The Second Quarter And Half Year 2015 8/26/2015
Verastem, Inc. (VSTM) To Present Data At The 16th World Conference On Lung Cancer 8/26/2015
Oncoceutics Release: Enrollment Begins In Expansion Phase Of ONC201 Clinical Trial 8/26/2015
FDA Grants Orphan Drug Designation For Tocagen Inc.'s Toca 511 & Toca FC, An Investigational Immuno-Oncology Treatment For Glioblastoma 8/25/2015
Clementia Expands Ongoing Phase 2 Study To Include Children With Fibrodysplasia Ossificans Progressiva (FOP) 8/25/2015
Chrono Therapeutics, Inc. Receives Second Fast Track SBIR Grant From National Cancer Institute For Patient-Individualized Smoking Cessation Therapy 8/25/2015
Regulus (RGLS) Appoints Michael Huang, M.D. As Vice President, Clinical Development 8/25/2015
Allergan (AGN) And Gedeon Richter Ltd. (RIG2.F) To Present Data From Cariprazine Trials At European College Of Neuropsychopharmacology (ECNP) Annual Meeting In Amsterdam 8/25/2015
Ascendis Pharma A/S Reports Second Quarter 2015 Financial Results 8/25/2015
Arbutus Biopharma (ABUS) Announces Initiation Of Patient Dosing In The TKM-PLK1 HCC Expansion Cohort 8/25/2015
CSL Behring Enrolls First Patient In Global Phase II/III Study Of rVIIa-FP For On-Demand Treatment Of Patients With Hemophilia A Or B With Inhibitors 8/25/2015
DelMar Pharmaceuticals To Present At The 17th Annual Rodman & Renshaw Global Investment Conference On September 9, 2015 8/25/2015
OncoSec Medical Inc. Promotes Sheela Mohan-Peterson To Chief Legal And Compliance Officer 8/24/2015
DelMar Pharmaceuticals To Present VAL-083 Lung Cancer Clinical Strategy At The 16th World Conference On Lung Cancer 8/24/2015
Esperance Pharmaceuticals, Inc. Announces Strategic Alliance With MD Anderson Cancer Center 8/24/2015
NMT Pharmaceuticals Singapore Announces Signing Of Letter Of Intent With CAO Pharmacueticals USA In Licensing And Development Of Anti-Cancer Drug CZ-48 8/24/2015
ReGen Biologics, Inc. (RGBI) BORIS Gene Silencing Technology Successfully Utilized By Independent Researchers To Kill Breast Cancer And Colon Cancer Stem Cells 8/24/2015
Genentech (RHHBY) Throws Cancers in a Basket to Detect Tumors at Their Genetic Roots 8/21/2015
HedgePath Pharmaceuticals Launches Clinical Trial For Its Proposed Cancer Treatment 8/21/2015
ProNAi Therapeutics, Inc. Reports Second Quarter 2015 Results 8/21/2015
Seres Therapeutics Announces FDA Orphan Drug Designation For SER-109 For The Prevention Of Recurrent Clostridium Difficile Infection in Adults 8/21/2015
Vernalis PLC (VNLPY.PK) Completes Investment In Its NCE Development Pipeline 8/20/2015
PharmaMar Announces License Agreement With Specialised Therapeutics Australia Pty For APLIDIN (plitidepsin) In Oncology 8/20/2015
S1 BioPharma (Formerly Known As S1 Pharmaceuticals, Inc.) Supports FDA Approval Of First-Ever Treatment For Hypoactive Sexual Desire Disorder 8/20/2015
The Leukemia & Lymphoma Society Applauds Encouraging Data From A Phase 2 Study Of Venetoclax For A High-Risk Subset Of Chronic Lymphocytic Leukemia Patients 8/20/2015
Enteris Biopharma's Formulation Technology Enables Oral Delivery Of Cara Therapeutics, Inc. (CARA)' CR845 Peptide In Phase 2 Trial In Osteoarthritis 8/20/2015
60 Degrees Pharmaceuticals To Begin Phase II Clinical Trials In Dengue Fever Patients 8/20/2015
Esperion (ESPR) Rockets as Lead Drug ETC-1002 Will Not Require Heart Trial for FDA Approval 8/19/2015
Madison Vaccines Announces Patient Dosing Underway In Clinical Trial Pairing Its Lead Prostate Cancer Vaccine, MVI-816, With PD1 Inhibitor Pembrolizumab 8/19/2015
Astex Pharmaceuticals (ASTX) Announces Publication Of Key Clinical Data For Guadecitabine (SGI-110) In The Lancet Oncology 8/19/2015
Corbus' Investigational Drug Resunab Granted Fast Track Status By The U.S. FDA For The Treatment Of Systemic Sclerosis 8/19/2015
FDA Grants Fast Track Designation To Cempra Pharmaceuticals, Inc. (CEMP) For Solithromycin In The Treatment Of Community Acquired Bacterial Pneumonia 8/19/2015
Esperion (ESPR) Provides Update On The ETC-1002 Development Program Following End-Of-Phase II Meeting With FDA 8/18/2015
Genentech (RHHBY)'s Atezolizumab Shrank Tumors in Phase II Lung Cancer Trial 8/18/2015
OncoSec Medical Inc. Announces First Patient Enrolled In Phase II Clinical Trial Evaluating Combination Of ImmunoPulse IL-12 And Anti-PD-1 Treatment 8/18/2015
Omeros Corporation (OMER) Announces Additional Positive Data In OMS721 Phase 2 Clinical Trial 8/18/2015
Armetheon Expands Leadership Team, Names Detlef Albrecht, M.D., As Chief Medical Officer 8/18/2015
TapImmune Inc. (TPIV) Completes Transfer of IND From The Mayo Clinic 8/18/2015
Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP And Fast Track Designations By FDA 8/18/2015
Remedy Pharmaceuticals, Inc. Initiates Phase IIA Study Of CIRARA In Spinal Cord Injury 8/18/2015
CytoDyn Release: First Self-Injectable HIV Antibody: 98% Success Rate In Phase 2b Clinical Trial, Could Be Commercial 8/18/2015
Pfenex (PFNX) Wins $143.5 Million Next-Gen Anthrax Vaccine Contract 8/17/2015
Avalanche Biotech (AAVL) Goes Back to Drawing Board, Performs More Preclinical Studies on Eye Drug 8/17/2015
Pivotal Phase II Study Showed Genentech (RHHBY)’s Investigational Immunotherapy Atezolizumab Shrank Tumors In People With A Specific Type Of Lung Cancer 8/17/2015
Cara Therapeutics, Inc. (CARA) Initiates Phase II Trial Of Oral CR845 In Osteoarthritis 8/17/2015
Tobira Therapeutics Inc. Announces Initiation Of ORION, A Phase 2a Study Of Cenicriviroc In Obese Patients With Suspected Fatty Liver Disease 8/17/2015
Relmada Therapeutics Receives Health Canada Clearance To Commence Multiple Ascending Dose Study With Promising NMDA Receptor Antagonist 8/17/2015
DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding From NRC-IRAP To Support Expanded Research Program With Lead Product Candidate VAL-083 8/17/2015
Recro Pharma (REPH) Reports Second Quarter 2015 Financial Results 8/17/2015
Amarantus BioSciences, Inc. Reports Second Quarter 2015 Financial Results And Business Overview 8/17/2015
Immune Pharmaceuticals, Inc. Announces Corporate Update; Second Quarter 2015 Financial Results And Highlights And Conference Call Details 8/17/2015
Invion Limited Completes Clinical Trial Of INV103 (ala-Cpn10) In Lupus Patients 8/17/2015
BioLineRx Ltd. Announces Initiation Of Phase 2b Trial For Novel AML Consolidation Treatment 8/17/2015
Prima Biomed (PRR.AX) Announces Commencement Of Milestones For IMP701 Program 8/17/2015
OncoGenex Pharmaceuticals Inc. (OGXI) Reports Financial Results For Second Quarter 2015 8/14/2015
CASI Pharmaceuticals  (CASI) Reports Second Quarter 2015 Financial Results 8/14/2015
Sophiris Bio Inc. (SPHS) Reports Second Quarter Financial Results 8/14/2015
Bellicum (BLCM) Provides Operational Update And Reports Financial Results For The Second Quarter Ended June 30, 2015 8/14/2015
Catabasis Pharmaceuticals, Inc. Reports Second Quarter 2015 Financial Results And Recent Corporate Highlights 8/14/2015
Addex Therapeutics (ADXN.SW) Dipraglurant Demonstrates Anxiolytic- And Antidepressant-Like Activity In Multiple Preclinical Models Relevant For Non-Motor Symptoms In Parkinson's Disease 8/14/2015
GlobeImmune (GBIM) Announces Second Quarter 2015 Results And Corporate Highlights 8/14/2015
FibroGen, Inc. (FGEN) Announces Second Quarter 2015 Financial Results 8/14/2015
Ultragenyx (RARE) Reports Second Quarter 2015 Financial Results And Corporate Update 8/14/2015
Genentech (RHHBY), AbbVie (ABBV) Confirm Venetoclax Met Primary Endpoint in Phase II Study 8/13/2015
BrainStorm Cell Therapeutics Inc. Reports Second Quarter 2015 Financial Results And Provides Corporate Update 8/13/2015
FibroGen, Inc. (FGEN) Release: Nephrology Dialysis Transplantation Reports Phase II Data Of Investigational Orally Active HIF-PHI Roxadustat (FG-4592) Shows Improved Hemoglobin Levels In Non-Dialysis CKD Subjects With Anemia 8/13/2015
Mologen AG (MOLGF.PK): First Half Of 2015 Defined By Study Progress And Capital Increase 8/13/2015
Eleven Biotherapeutics (EBIO) Reports Second Quarter 2015 Financial Results 8/13/2015
VBL Therapeutics (VBLX) Announces Second Quarter 2015 Financial Results And Provides Business Update 8/13/2015
Opexa Therapeutics (OPXA) Reports Second Quarter 2015 Financial Results And Provides Corporate Update 8/13/2015
Viking Therapeutics (VKTX) Reports Second Quarter 2015 Financial Results And Provides Corporate Update 8/13/2015
Heat Biologics Announces Financial Results For The Second Quarter Ended June 30, 2015 8/13/2015
Argos Therapeutics, Inc. (ARGS) Reports Second Quarter 2015 Financial Results And Operational Highlights 8/13/2015
BioLineRx Ltd. To Report Second Quarter 2015 Results On August 20, 2015 8/13/2015
Juno (JUNO) Reports Second Quarter 2015 Financial Results 8/13/2015
BioClin Therapeutics Initiates Phase 2 Clinical Trial Evaluating B-701 For Treatment Of Urothelial Cell Carcinoma 8/12/2015
AbbVie (ABBV) Release: Phase 2 Study Of Venetoclax In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia With 17p Deletion Meets Primary Endpoint 8/12/2015
Tobira Therapeutics Inc. Reports Second Quarter 2015 Financial Results 8/12/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: New Publication Elaborates On TB4's Effects On Dry Eye Syndrome And Other Potential Ophthalmic Disorders 8/12/2015
Celator Pharmaceuticals, Inc. Announces Second Quarter 2015 Financial Results And Business Update 8/12/2015
Ardelyx (ARDX) Reports Second Quarter 2015 Financial Results 8/12/2015
Soligenix (SNGX) Announces Recent Highlights and Second Quarter 2015 Financial Results 8/12/2015
RXi Pharmaceuticals (RXII) Reports Second Quarter 2015 Financial Results And Business Highlights 8/12/2015
Immune Design Corporation (IMDZ) Announces Phase II Cancer Immunotherapy Trial Collaboration 8/12/2015
Japan Grants Safety Clearance To Pluristem Therapeutics (PSTI)'s PLX-PAD Cells For Use In Clinical Trials 8/12/2015
CMC Biologics Enters Into Agreement With The PATH Malaria Vaccine Initiative For Accelerated Development And Manufacturing Of Monoclonal Antibodies 8/12/2015
InSite Vision (ISV) Reports Second Quarter 2015 Financial Results 8/12/2015
Exelixis (EXEL) Announces Second Quarter 2015 Financial Results And Provides Corporate Update 8/12/2015
Aurinia (ISA.TO) Reports Second Quarter 2015 Financial Results 8/12/2015
Akebia Therapeutics, Inc. (AKBA) Announces Second Quarter 2015 Financial Results 8/12/2015
Viamet To Present At American Chemical Society National Meeting 8/12/2015
GenSpera Provides 2nd Quarter Corporate Update 8/12/2015
Ischemix Elects Peter G. Milner, MD To Board Of Directors 8/12/2015
Theravance Biopharma, Inc. Reports Second Quarter 2015 Financial Results And Provides Business Update 8/12/2015
ARCA biopharma Announces Second Quarter 2015 Operating Results And Provides Update On Recent Accomplishments 8/12/2015
Adynxx Reports Positive Results For Phase 2b Study Of AYX1 8/11/2015
BioClin Therapeutics Initiates Phase 2 Clinical Trial Evaluating B-701 For Treatment Of Urothelial Cell Carcinoma 8/11/2015
Novavax (NVAX) Announces Positive Top-Line Data From Phase 2 RSV F-Protein Vaccine Clinical Trial In Older Adults 8/11/2015
Portage Biotech's Biohaven Raises $ 4.1 Million In First Tranche Of Private Placement. Portage Invests $ 2.5 Million 8/11/2015
Asterias Biotherapeutics Reports Second Quarter Results 8/11/2015
Merrimack (MACK) Reports Second Quarter 2015 Financial Results 8/11/2015
Lion Biotechnologies, Inc. Announces Second Quarter 2015 Financial Results 8/11/2015
Omeros Corporation (OMER) Reports Second Quarter 2015 Financial Results 8/11/2015
Discovery Laboratories (DSCO) Provides Business Update And Reports Second Quarter 2015 Financial Results 8/11/2015
Ignyta (RXDX) Announces Second Quarter 2015 Company Highlights And Financial Results 8/11/2015
Ocular Therapeutix (OCUL) Reports Second Quarter 2015 Financial Results 8/11/2015
Puma Biotech (PBYI) Reports Second Quarter 2015 Financial Results 8/11/2015
AEterna Zentaris (AEZS) Announces Data And Safety Monitoring Board Scheduled To Complete Second Interim Analysis Of The ZoptEC Phase 3 Trial In Endometrial Cancer In Early October 8/11/2015
Threshold Pharmaceuticals, Inc. (THLD) And ATOMIC Initiate First Phase 2 Clinical Trial Of Tarloxotinib Bromide (TH-4000) In Patients With Advanced EGFR-Mutant, T790M-Negative Non-Small Cell Lung Cancer (NSCLC) 8/11/2015
BioTime (BTX) Reports Second Quarter 2015 Results And Recent Developments 8/11/2015
Trevena, Inc. (TRVN) Reports Second Quarter 2015 Financial Results And Provides A Corporate Update 8/11/2015
Bio-Path Holdings, Inc. (BPTH) Reports Second Quarter 2015 Operational And Financial Results 8/11/2015
Celldex (CLDX) Reports Second Quarter 2015 Results 8/11/2015
Cara Therapeutics, Inc. (CARA) Reports Second Quarter 2015 Financial Results 8/11/2015
Anthera Pharmaceuticals, Inc. (ANTH) Reports 2015 Second Quarter And Operational Update 8/11/2015
BioSpecifics Technologies Corporation (BSTC) Reports Second Quarter 2015 Financial Results 8/11/2015
BrainStorm Cell Therapeutics Inc. Announces Completion Of Enrollment In Phase 2 Clinical Trial Of NurOwn in ALS 8/11/2015
Bay Area's XOMA (US) LLC (XOMA) to Cut Jobs and Change Focus in Light of Q2 Filings and Stock Drop 8/10/2015
Karyopharm (KPTI) Tanks After Cancer Drug Trial Patients Get Sepsis 8/10/2015
Intrexon Corporation And Synthetic Biologics, Inc. (SYN) Enter ECC To Develop Novel Biotherapeutics For Treatment Of Phenylketonuria 8/10/2015
Galectin Therapeutics Provides Phase II NASH Program Update and Reports Second Quarter 2015 Financial Results 8/10/2015
Celsion Corporation (CLSN) And myTomorrows Expand ThermoDox European Early Access Program To Include Patients With Primary Liver Cancer And Liver Cancer Metastases 8/10/2015
Syntethic Biologics, Inc. Reports Second Quarter 2015 Financial Results And Operational Highlights 8/10/2015
NeuralStem Inc. Reports Second Quarter 2015 Financial Results 8/10/2015
Celsion Corporation (CLSN) Reports Second Quarter 2015 Financial Results And Provides Business Update 8/10/2015
Verastem, Inc. (VSTM) Reports Second Quarter 2015 Financial And Corporate Results 8/10/2015
MabVax Therapeutics Holdings Provides Corporate Update And Reports Second Quarter 2015 Financial Results 8/10/2015
AVEO Oncology (AVEO) Reports Second Quarter 2015 Financial Results 8/10/2015
KaloBios Pharmaceuticals, Inc. (KBIO) Reports Second Quarter Financial Results And Provides Clinical Update 8/10/2015
Pluristem Therapeutics (PSTI) In Key Discussions With Europe's Adaptive Pathways Group On Phase II Protocol In Critical Limb Ischemia 8/10/2015
GlycoMimetics, Inc. (GLYC) Reports Second Quarter 2015 Results 8/7/2015
Symbiomix' First Pivotal Trial Results For SYM-1219 For Bacterial Vaginosis Presented At IDSOG 8/7/2015
Mirati Therapeutics  (MRTX) Reports Second Quarter 2015 Financial Results And Provides Business Update 8/7/2015
Lexicon Pharma (LXRX) Reports 2nd Quarter Financial Results, Provides Clinical Pipeline Update 8/7/2015
GenVec Inc. (GNVC) Reports Second Quarter 2015 Financial Results 8/7/2015
Clovis Oncology (CLVS) Announces Second Quarter 2015 Operating Results 8/7/2015
NephroGenex (NRX) To Host Conference Call And Webcast On Second Quarter 2015 Financial Results On Thursday, August 13, 2015 8/7/2015
bluebird bio (BLUE) Reports Second Quarter 2015 Financial Results And Recent Operational Progress 8/7/2015
Cerulean Pharma Inc. (CERU) Reports Second Quarter 2015 Corporate Highlights And Financial Results 8/7/2015
Cytori Therapeutics, Inc. (CYTX) Reports Second Quarter 2015 Business and Financial Results 8/7/2015
Ohr Pharma (OHRP) Reports Fiscal Third Quarter 2015 Financial And Business Results 8/7/2015
La Jolla Pharma (LJPC) Announces Second Quarter 2015 Financial Results And Recent Corporate Progress 8/7/2015
Athersys (ATHX) Reports Second Quarter 2015 Results 8/7/2015
ChemoCentryx, Inc. (CCXI) Reports Second Quarter 2015 Financial Results And Provides Corporate Update 8/7/2015
Medivation, Inc. (MDVN) Reports Second Quarter 2015 Financial Results 8/7/2015
Ocata Therapeutics Provides Corporate Update For The Second Quarter Of 2015 8/7/2015
CTI BioPharma Reports Second Quarter 2015 Financial Results 8/7/2015
Spectrum Pharmaceuticals, Inc. (SPPI) Reports Second Quarter 2015 Financial Results And Pipeline Update 8/7/2015
Alnylam (ALNY) Reports Second Quarter 2015 Financial Results And Highlights Recent Period Activities 8/7/2015
Heron (HRTX) Announces Second Quarter 2015 Financial Results And Recent Corporate Progress 8/7/2015
Three Patients Dropped Out of Alnylam (ALNY)'s Phase II Trial for Revusiran 8/7/2015
MabVax Therapeutics, Inc. And The Rockefeller University Enter Into A Collaborative Research Agreement 8/6/2015
Cold Genesys, Inc. Secures Series B Investment 8/6/2015
Arena Pharmaceuticals, Inc. (ARNA) Reports Second Quarter 2015 Financial Results And Provides Corporate Update 8/6/2015
Sangamo BioSciences (SGMO) Reports Second Quarter 2015 Financial Results 8/6/2015
Apricus Biosciences (APRI) Provides Corporate Update And Second Quarter 2015 Financial Results 8/6/2015
Conatus Pharma Reports Second Quarter 2015 Financial Results And Program Updates 8/6/2015
Alder Biopharma Reports Second Quarter 2015 Financial And Operating Results 8/6/2015
TRACON Pharmaceuticals, Inc. (TCON) Reports Second Quarter 2015 Financial Results And Provides Corporate Update 8/6/2015
Galapagos (GLPG.BR) Release: Patient Recruitment Completed In FITZROY Phase 2 Crohn's Disease Study With Filgotinib 8/6/2015
Apitope Announces Completion Of Enrolment In Phase IIA Clinical Trial Of ATX-MS-1467 In Relapsing Multiple Sclerosis 8/6/2015
Opko Health (OPK) Release: Two Reports On hGH-CTP Pediatric Phase 2 Clinical Data Accepted For Oral Presentation At The 54th Annual Meeting Of The European Society For Paediatric Endocrinology (ESPE Conference) 8/6/2015
Nuvo Research Inc. (NRI.TO) Announces 2015 Second Quarter Results 8/6/2015
Theravance Biopharma Receives FDA Fast Track Designation For TD-8954 For Use With Enteral Feeding In Critically Ill Patients 8/6/2015
Idera Pharmaceuticals, Inc. (IDRA) Reports Second Quarter 2015 Financial Results And Provides Corporate Update 8/6/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) Provides Update On Clinical Trials In U.S., Korea And China 8/6/2015
Opko Health (OPK) Announces Second Quarter Operating And Financial Results 8/6/2015
Ironwood (IRWD) Provides Second Quarter 2015 Investor Update 8/6/2015
XenoPort, Inc. (XNPT) Reports Second Quarter Financial Results 8/6/2015
Synta (SNTA) Reports Second Quarter 2015 Financial Results 8/6/2015
GTX Corp Provides Corporate Update And Reports Second Quarter 2015 Financial Results 8/6/2015
Acceleron Pharma Reports Second Quarter 2015 Financial And Operational Results 8/6/2015
Seres Therapeutics Reports Second Quarter 2015 Financial Results And Provides Business Update 8/6/2015
BIND Therapeutics (BIND) Reports Second Quarter 2015 Financial Results And Provides Corporate Update 8/6/2015
Aerie (AERI) To Present At The Canaccord Genuity Growth Conference 8/6/2015
Infinity Pharmaceuticals Inc. (INFI) Provides Company Update And Reports Second Quarter 2015 Financial Results 8/6/2015
Genocea Biosciences Reports Second Quarter 2015 Financial Results 8/6/2015
Acadia (ACAD) Announces Publication Of Data From Its -015 Open Label Safety Study In Parkinson’s Disease Psychosis In The Journal Of The American Medical Directors Association 8/6/2015
Aurinia (ISA.TO) To Present At The Canaccord Genuity 35th Annual Growth Conference 8/6/2015
Fate Therapeutics (FATE) Reports Second Quarter 2015 Financial Results 8/6/2015
Mast Therapeutics (MSTX) To Host Second Quarter 2015 Financial Results And Corporate Update Conference Call 8/6/2015
University of California, San Francisco (UCSF) To Study Halozyme (HALO) PEGPH20 In Pancreatic Cancer Patients Who Are Candidates For Potentially Curative Surgery 8/6/2015
Aquinox (AQXP) Announces Positive Results From Secondary Endpoints From Phase II LEADERSHIP Trial In BPS/IC And Reports Second Quarter 2015 Financial Results 8/6/2015
Ariad (ARIA) Reports Second Quarter 2015 Financial Results And Progress On Strategic Objectives 8/5/2015
MabVax Therapeutics, Inc. Issues Letter To Stockholders 8/5/2015
Karuna Receives Wellcome Trust Award To Advance Innovative Clinical Stage Product Candidate For The Treatment Of Schizophrenia 8/5/2015
Pharmaxis (PXS.AX) And Synairgen plc Announce Research Collaboration To Develop LOXL2 Inhibitor For Pulmonary Fibrosis 8/5/2015



//-->